menu search

HIMS / This Telehealth Stock's Rapid Product Launches Should Benefit Investors

This Telehealth Stock's Rapid Product Launches Should Benefit Investors
Hims and Hers is rapidly expanding its brand across multiple healthcare categories. Read More
Posted: Apr 1 2022, 11:53
Author Name: The Motley Fool
Views: 112022

HIMS News  

Hims & Hers: A Promising Company With Resolvable Challenges

By Seeking Alpha
November 2, 2023

Hims & Hers: A Promising Company With Resolvable Challenges

While HIMS showcases robust performance, its ability to navigate and mitigate associated risks will be pivotal in securing its future success. Major r more_horizontal

Hims & Hers: Specialization Is The Secret To Great Growth

By Seeking Alpha
October 24, 2023

Hims & Hers: Specialization Is The Secret To Great Growth

Hims & Hers Health offers personalized and customized telehealth services, specializing in niche treatments for hair loss, erectile dysfunction, skinc more_horizontal

Is Hims & Hers Health Stock a Buy Now?

By The Motley Fool
October 3, 2023

Is Hims & Hers Health Stock a Buy Now?

Hims & Hers is cutting prices, but profit margins are rising. The company is cash flow positive, with plenty of cash on the balance sheet. more_horizontal

Hims & Hers Health: Risks Remain, But Upgrading To Buy

By Seeking Alpha
September 20, 2023

Hims & Hers Health: Risks Remain, But Upgrading To Buy

Hims & Hers reported strong earnings and raised its full-year guidance, but its stock continues to decline. Hims & Hers is focusing on personalization more_horizontal

Hims & Hers: Myopic Shorts, Absurdly Cheap

By Seeking Alpha
September 20, 2023

Hims & Hers: Myopic Shorts, Absurdly Cheap

Hims & Hers Health, Inc. is rapidly growing and becoming more profitable, making it a cheaply valued stock with minimal risk. A recent short report qu more_horizontal

The Market Is Wrong On Hims & Hers Health

By Seeking Alpha
September 17, 2023

The Market Is Wrong On Hims & Hers Health

Hims & Hers managed to grow revenue every year by at least 80%. However, it's still trading below its initial price when became publicly traded via SP more_horizontal

Is This Underrated SPAC Deal Stock a No-Brainer Buy?

By The Motley Fool
September 6, 2023

Is This Underrated SPAC Deal Stock a No-Brainer Buy?

Hims & Hers Health went public through a SPAC merger a couple of years ago. Since then, the stock is down 60%. more_horizontal

Hims & Hers: Buying With Both Fists (Double Rating Upgrade)

By Seeking Alpha
August 21, 2023

Hims & Hers: Buying With Both Fists (Double Rating Upgrade)

Hims & Hers Health reported a strong Q2 and raised guidance, but the stock has sold off sharply. The company is expanding into new product categories more_horizontal


Search within

Pages Search Results: